Plandaí Biotechnology, Inc. Provides Shareholder Update on Completion of the Company’s Production Facility and Start of Commercial Production
August, 6
The Update Also Provides New Information on Studies Involving Plandaí Products, Including an Upcoming Phase II Human Clinical Trial
SEATTLE, WA / ACCESSWIRE / August 6, 2014 / Plandaí Biotechnology, Inc. (PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today provided an update to shareholders that covers topics including the completion and optimization of the company’s state-of-the-art production facility in South Africa and the schedule for commencement of commercial production at the facility.
According to company spokesperson Louise Willemse, contractors are expected to finish all installation work at the company’s production facility on the Senteeko Tea Estate in South Africa between August 8 and Aug 15, 2014. The installation work includes all electrical, steam lines, equipment installation, and boiler system.
Engineers from the Indian contractor are scheduled to arrive on-site during the week of August 17 to complete the optimization and to initiate start-up of the facility. This process is anticipated to be complete during the first half of September 2014.
Commercial production of the Phytofare(TM) Catechin extract is then expected to commence with the first green tea crop of the season, which is entirely weather dependent but is anticipated to begin sometime in late September 2014 and continue through May of 2015. During the next winter season in South Africa, June through August 2015, the Company will begin processing Eureka lemons to produce approximately 200 kg of Phytofare(TM) Limonoid Glycoside Complex per day.
In addition to releasing the factory update, Plandaí also announced that the first two legs of the human clinical trial on the oral bioavailability of the company’s Phytofare™ Catechin Complex have been completed and results are expected to be released during the week of August 17, 2014. The third and final leg of the study will take place using Phytofare™ extract produced at the Senteeko facility and then entrapped in Pheroid® by scientists at North-West University in Potchefstroom, South Africa.
Concurrent with the third leg of the bioavailability study, Plandaí expects to commence a study testing the effects of Phytofare(TM) Catechin Complex in inducing weight loss. The study is being designed as a Phase II human clinical trial and will involve 100 patients over 90 days in a double-blind protocol.
